The UroLift®System - EMEA

NeoTract, Inc., based in Pleasanton, California, manufactures the UroLift® System, a minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). This innovative system uses a mechanical implant to lift and hold enlarged prostate tissue, allowing for improved urine flow without cutting or removing tissue, thus preserving sexual function. The UroLift System is available in various regions, including Europe, the United States, Canada, and Australia. It is designed for outpatient procedures, typically performed under local anesthesia, and does not require catheterization or an overnight hospital stay. The system is suitable for a wide range of prostate anatomies and has demonstrated safety and effectiveness, with clinical data supporting symptom relief for up to five years. Targeted at men seeking alternatives to medication or more invasive surgeries, the UroLift System is promoted by Teleflex Interventional Urology, which focuses on providing innovative urology devices to healthcare providers and clinics.

• Employees 1